Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | FPR1 | P21462 | 3/20 | 0.38 |
| ▸ | FPR2 | P25090 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | KCNJ6 | P48051 | 3/20 | 0.36 |
| ▸ | KCNJ5 | P48544 | 3/20 | 0.36 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3954506 | 0.89 | EPHX2 (0.46) | CCR3EPHX2EPHX1FPR1FPR2 | |
| SCHEMBL3957210 | 0.88 | FPR1 (0.48) | NPC1RAB9ASMN1; SMN2EPHX2EPHX1 | |
| SCHEMBL3953261 | 0.88 | EPHX2 (0.41) | NPC1RAB9ASMN1; SMN2EPHX2EPHX1 | |
| SCHEMBL3950790 | 0.86 | TRPV1 (0.39) | NPC1RAB9ASMN1; SMN2DPP4POLB | |
| SCHEMBL3958772 | 0.85 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2CCR3FPR1 | |
| SCHEMBL3953790 | 0.82 | TRPV1 (0.41) | NPC1RAB9ASMN1; SMN2LMNADPP4 | |
| SCHEMBL3951491 | 0.82 | RAB9A (0.44) | NPC1RAB9ASMN1; SMN2FPR1FPR2 | |
| SCHEMBL3955061 | 0.74 | CNR1 (0.43) | RAB9ASMN1; SMN2CCR3EPHX2LMNA | |
| SCHEMBL4150432 | 0.74 | ALDH1A1 (0.41) | NPC1RAB9ASMN1; SMN2KCNJ6KCNJ5 | |
| SCHEMBL13905013 | 0.74 | ALDH1A1 (0.41) | NPC1RAB9ASMN1; SMN2KCNJ6KCNJ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009032754-A2 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032754-A2 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | NPC1 651/4885RAB9A 719/4885SMN1; SMN2 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.